RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
← Comparisons

Semax vs Selank

Two Russian-developed regulatory peptides: one studied for neuroprotection, the other for anxiety.

Research use only. A summary of published literature for educational reference — not medical advice and not a guide to human use.

The short version

Semax is an ACTH(4-10) analog studied for neuroprotection and attention. Selank is a tuftsin analog studied for anxiolytic and immune-modulating effects. Both are approved in Russia and unapproved elsewhere.

At a glance

Parent molecule

ACTH(4-10) fragment + Pro-Gly-Pro

Tuftsin + Pro-Gly-Pro

Research focus

Neuroprotection, BDNF expression, stroke recovery

Anxiety, GABAergic modulation, immune signalling

Approval status

Approved in Russia; not FDA/EMA

Approved in Russia; not FDA/EMA

Typical route studied

Intranasal

Intranasal

Research vial sizes

5 / 10 mg

5 / 10 mg

01How they work

Semax research reports increased BDNF and its receptor in rodent brain, and melanocortin-related signalling. Selank research reports effects on GABA-A receptor gene expression and enkephalin breakdown.

02What studies measured

Semax has been studied in stroke-recovery cohorts and animal cognition models. Selank studies compared it with benzodiazepines in generalized anxiety and reported similar anxiolytic scores without sedation in small trials.

03Reported side effects

Published reports describe both as well tolerated, but trials are small and mostly from a single country's research groups.

04Approval & evidence status

Both are on the Russian drug register. Neither has Western regulatory approval or large independent trials.

Citations

  1. [1]Animal study2006

    Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

    Dolotov OV, et al. Brain Res, 2006.

    Read paper ↗
  2. [2]Randomized comparative clinical trial (Russian-language)2008

    Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders

    Zozulia AA, et al. Zh Nevrol Psikhiatr Im S S Korsakova, 2008.

    Read paper ↗

Research use only. A summary of published literature for educational reference — not medical advice and not a guide to human use.